- Email: [email protected]
Spontaneous regression of small cell lung cancer
Abstracts/Lung
Cancer
60-120 min following the glucose load was significantly reduced atter D-adrcnergic inhibition from 103i28 pm01 100 g’ 60 min-’ to29i29 pmol 100 g’ 6Omis’ (P~3.05). Thenoreadrenahneconcentrationin thearterial blood was not increased in the baseline period compared to healthy elderly; it increased following the glucose load while there was no demonstrable increase in adrenaline concentration in the two experiments. It is suggested that these patients have increased sensitivity of the Oadrenergic receptors and an early facultative component of the glucoseinduced thermogenesis in part takes place in the forearm.
DNA polymerase a as ao independent prognostic paruneter in noosmall cell lung caocer - ao immuoohistochemical study lhteishi M, Ishida T, Hamatake M, Fukuyama Y, Kodono S, Sugimachi K et al.Department of Surgery II. Faculty of Medicine, Kyushu Universi& 3-I-l Maidashi, Higashiku, Fukuoka 812. Eur J Surg Oncol 1994;20.4616 We examined 70 fresh frozen sections of primary non-small cell lung cancer using a monoclonai antii for DNA polymer-am o( (PGL a). The tumors were divided into two groups; those with more than 5% of PGL a positive cells were designated as PGL CL(+), while those with less than 5% were PGL a (-). PGL a (+) tumors were obtained in 33 (47%) cases. The incidence of PGL a (+) in male patients was statistically higher than in females (p < 0.01). The incidence also correlated with the T (tumor) status; Tl < T2, Tl < T4, with a signifcance (P < 0.05). Basedon data on 70 patients, the 5-year smvival rates of POL a (+) and PGL a (-) were. 36% and 63% respectively @ < 0.05). In 48 patients with adenocarcinoma, the 5-year survival rates of PGL a (+) and PGL a (-) were 25% and 60%, respectively (F < 0.05). In addition, in 26 patients with a tumor size of less than 3 cm, the 5-year smvival fates of PGL a. (+) and PGL a (-) were 13% and 74%, respectively (F < 0.01). To compare the prognostic signiticance of the variables, a muhivariate analysis was used to show significance for~valinPOLa@<0.05).OurQtashowthatinron-smallceUlung cancer, PGL a expression is associated with the extent of malignancy and survival. Therefore, PGL a is considered to be a useful prognostic parameter.
The utility of bone marrOw sciotigrapby aod mngoetic resooaoce imaging for ooo-invasive dingooais of bone mamw Bathmann J, Sigmund G. Abteilung Nukleatmedtzin, Albert-LudwigsUniversitat, Hugstetter Strasse 55, 79106 FreibuR. Aktuel Radio1 1994;4: 159-68. This article provides an overview of the possibilities and indications for magnetic resonance imaging (MRI) and bone marrow scintigraphy in imaging the bone marrow. After a brief review of the anatomical and physiologic structures of bone marrow, the principles of both methods are described. The radiophamtaceuticals of choice for bone marrow scintigraphy are the newly developed 99”Tc-labelled antigranulocyte monoclonal antibodies, They allow a high-quality, whole-body visualization of haematopoietically active bone marrow by specifically targeting granulopoietic bone marrow cells and mature grantdocytes. MRI enables us to visualize the bone marrow with high contrast and spatial resolution by assessing different properties of the biological tissue - mainly fat, water, and mineral content. Both methods provide a noninvasive and sensitive approach for imaging the bone marrow in different benign and malignant disorders.
I2 (1995)
113-160
137
Spoataoeous Tression of small cell lung caocer Nomura M, Fujimura M, Matsuda T, Nonomura A, Kitagawa M, Nakamwa H et al. Thini Dept. of Internal Medicine, Kanazawo Univ. School oJMedicine, Kanazawa. Jpn. J. Thorac Dis. 1994;32: 324-7. An 82-year-old man was admitted for evaluation of dry cough and low grade fever. A chest roentogenogram obtained on admission revealed an abnormal mass shadow at the left hilts. Trans-bronchial lung biopsy was used to make a diagnosis of small cell lung cancer. This tumor regressed spontaneously.
Use of the imomaotoxio N!%ll-blocked ricio io patients with smallcell lung caocer Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V et al. ImmunoGen, Inc., Boston, u4. Int J Cancer 1994;57:Suppl. 857-9. In patients with small-cell lung cancer (SCLC), relapse with resistant disease often causes death. N9Ol-blocked ricin (N9Ol-bR). a murine monoclonal antibtxly (MAb)-blocked ricin immunotoxin, is a potential therapeutic for SCLC. N9Ol-bR targets CD56, present on SCLC and cells of neuro-ectodennal origin. N901-bR kills up to 5 logs of CD56positive cells at a concentration of 0.25 nM, while CDM-negative cells require lOOO-fold more drug to achieve similar cell kill. We treated 21 patients with relapsed or refractory SCLC with a single 7day course of N90 l-bR as a continuous infusion. We determined the MTD and toxicity profile, demonstrated drug binding to tumor cells in biopsies of lung, liver and bone marrow, and determined the time to development of human anti-mouse and anti-ricin antibodies. One patient had a documented PR and 6 patients demonstrated stable disease. Toxicity included transient elevation of liver enzymes, mild thrombocytopenia, hypoalbuminemia, fever, malaise, and evidence of capillary leak syndrome. Toxicities were controllable and reversible. No apparent drugrelated central- or peripheralnervous-system toxicity was noted by serial neurologic examinations, EMGs, and nerve conduction studies. Trials of N901-bR are planned in SCLC patients achieving CR and PR following chemoradiotherapy, and in relapsed/refractory patients. AntiB4-bRwill be added as an immunosuppressant in order to permit delivery of multiple courses ofN90 l-tR. Additional trials will investigate synergy with conventional chemotherapeutics and the use of N901-bR as a sensitizing agent for chemotherapy-resistant tumors.
Small cell lung caocer with paraoeoplastic oepbrotic syndrome Boon ES, Vrij AA, Nieuwhof C, Van Noord JA, Zeppenfeldt E. Department ofRespiratory Diseases, De Wever Hospital, Postbus 4446, NL-MOI CXHeerlen. Eur Fkspir J 1994;7:1192-3. We present a case of nephrotic syndrome, associated with small cell lung carcinoma. Renal biopsy revealed membranous glomerulonephritis, probably due to immune complex deposition with tumour antigen. Complete remission of the small cell lung carcinoma after chemotherapy was followed by regression of the nephrotic syndrome. This regression persisted even when brain metastases developed, without simultaneous relapse of tumour outside the central nervous system.
K-ras geoe mutationa: Ao unfavorable prognostic marker in stage I lung adeoocarcinoma Silini EM, Bosi F, Pellegata NS, Mlpato G, Roman0 A, Namri S et al. Department of Human Pathology. University of Pavia, IRCCS Policlinico S Matteo, I-27100 Povia. Wrchows Arch 1994;424:36773. Activation of K-ras gene by point mutations, a wmmon finding in hmg adenocarcinomas, has been suggested to decrease patient survival. We
Cancer
60-120 min following the glucose load was significantly reduced atter D-adrcnergic inhibition from 103i28 pm01 100 g’ 60 min-’ to29i29 pmol 100 g’ 6Omis’ (P~3.05). Thenoreadrenahneconcentrationin thearterial blood was not increased in the baseline period compared to healthy elderly; it increased following the glucose load while there was no demonstrable increase in adrenaline concentration in the two experiments. It is suggested that these patients have increased sensitivity of the Oadrenergic receptors and an early facultative component of the glucoseinduced thermogenesis in part takes place in the forearm.
DNA polymerase a as ao independent prognostic paruneter in noosmall cell lung caocer - ao immuoohistochemical study lhteishi M, Ishida T, Hamatake M, Fukuyama Y, Kodono S, Sugimachi K et al.Department of Surgery II. Faculty of Medicine, Kyushu Universi& 3-I-l Maidashi, Higashiku, Fukuoka 812. Eur J Surg Oncol 1994;20.4616 We examined 70 fresh frozen sections of primary non-small cell lung cancer using a monoclonai antii for DNA polymer-am o( (PGL a). The tumors were divided into two groups; those with more than 5% of PGL a positive cells were designated as PGL CL(+), while those with less than 5% were PGL a (-). PGL a (+) tumors were obtained in 33 (47%) cases. The incidence of PGL a (+) in male patients was statistically higher than in females (p < 0.01). The incidence also correlated with the T (tumor) status; Tl < T2, Tl < T4, with a signifcance (P < 0.05). Basedon data on 70 patients, the 5-year smvival rates of POL a (+) and PGL a (-) were. 36% and 63% respectively @ < 0.05). In 48 patients with adenocarcinoma, the 5-year survival rates of PGL a (+) and PGL a (-) were 25% and 60%, respectively (F < 0.05). In addition, in 26 patients with a tumor size of less than 3 cm, the 5-year smvival fates of PGL a. (+) and PGL a (-) were 13% and 74%, respectively (F < 0.01). To compare the prognostic signiticance of the variables, a muhivariate analysis was used to show significance for~valinPOLa@<0.05).OurQtashowthatinron-smallceUlung cancer, PGL a expression is associated with the extent of malignancy and survival. Therefore, PGL a is considered to be a useful prognostic parameter.
The utility of bone marrOw sciotigrapby aod mngoetic resooaoce imaging for ooo-invasive dingooais of bone mamw Bathmann J, Sigmund G. Abteilung Nukleatmedtzin, Albert-LudwigsUniversitat, Hugstetter Strasse 55, 79106 FreibuR. Aktuel Radio1 1994;4: 159-68. This article provides an overview of the possibilities and indications for magnetic resonance imaging (MRI) and bone marrow scintigraphy in imaging the bone marrow. After a brief review of the anatomical and physiologic structures of bone marrow, the principles of both methods are described. The radiophamtaceuticals of choice for bone marrow scintigraphy are the newly developed 99”Tc-labelled antigranulocyte monoclonal antibodies, They allow a high-quality, whole-body visualization of haematopoietically active bone marrow by specifically targeting granulopoietic bone marrow cells and mature grantdocytes. MRI enables us to visualize the bone marrow with high contrast and spatial resolution by assessing different properties of the biological tissue - mainly fat, water, and mineral content. Both methods provide a noninvasive and sensitive approach for imaging the bone marrow in different benign and malignant disorders.
I2 (1995)
113-160
137
Spoataoeous Tression of small cell lung caocer Nomura M, Fujimura M, Matsuda T, Nonomura A, Kitagawa M, Nakamwa H et al. Thini Dept. of Internal Medicine, Kanazawo Univ. School oJMedicine, Kanazawa. Jpn. J. Thorac Dis. 1994;32: 324-7. An 82-year-old man was admitted for evaluation of dry cough and low grade fever. A chest roentogenogram obtained on admission revealed an abnormal mass shadow at the left hilts. Trans-bronchial lung biopsy was used to make a diagnosis of small cell lung cancer. This tumor regressed spontaneously.
Use of the imomaotoxio N!%ll-blocked ricio io patients with smallcell lung caocer Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V et al. ImmunoGen, Inc., Boston, u4. Int J Cancer 1994;57:Suppl. 857-9. In patients with small-cell lung cancer (SCLC), relapse with resistant disease often causes death. N9Ol-blocked ricin (N9Ol-bR). a murine monoclonal antibtxly (MAb)-blocked ricin immunotoxin, is a potential therapeutic for SCLC. N9Ol-bR targets CD56, present on SCLC and cells of neuro-ectodennal origin. N901-bR kills up to 5 logs of CD56positive cells at a concentration of 0.25 nM, while CDM-negative cells require lOOO-fold more drug to achieve similar cell kill. We treated 21 patients with relapsed or refractory SCLC with a single 7day course of N90 l-bR as a continuous infusion. We determined the MTD and toxicity profile, demonstrated drug binding to tumor cells in biopsies of lung, liver and bone marrow, and determined the time to development of human anti-mouse and anti-ricin antibodies. One patient had a documented PR and 6 patients demonstrated stable disease. Toxicity included transient elevation of liver enzymes, mild thrombocytopenia, hypoalbuminemia, fever, malaise, and evidence of capillary leak syndrome. Toxicities were controllable and reversible. No apparent drugrelated central- or peripheralnervous-system toxicity was noted by serial neurologic examinations, EMGs, and nerve conduction studies. Trials of N901-bR are planned in SCLC patients achieving CR and PR following chemoradiotherapy, and in relapsed/refractory patients. AntiB4-bRwill be added as an immunosuppressant in order to permit delivery of multiple courses ofN90 l-tR. Additional trials will investigate synergy with conventional chemotherapeutics and the use of N901-bR as a sensitizing agent for chemotherapy-resistant tumors.
Small cell lung caocer with paraoeoplastic oepbrotic syndrome Boon ES, Vrij AA, Nieuwhof C, Van Noord JA, Zeppenfeldt E. Department ofRespiratory Diseases, De Wever Hospital, Postbus 4446, NL-MOI CXHeerlen. Eur Fkspir J 1994;7:1192-3. We present a case of nephrotic syndrome, associated with small cell lung carcinoma. Renal biopsy revealed membranous glomerulonephritis, probably due to immune complex deposition with tumour antigen. Complete remission of the small cell lung carcinoma after chemotherapy was followed by regression of the nephrotic syndrome. This regression persisted even when brain metastases developed, without simultaneous relapse of tumour outside the central nervous system.
K-ras geoe mutationa: Ao unfavorable prognostic marker in stage I lung adeoocarcinoma Silini EM, Bosi F, Pellegata NS, Mlpato G, Roman0 A, Namri S et al. Department of Human Pathology. University of Pavia, IRCCS Policlinico S Matteo, I-27100 Povia. Wrchows Arch 1994;424:36773. Activation of K-ras gene by point mutations, a wmmon finding in hmg adenocarcinomas, has been suggested to decrease patient survival. We